Achillion Pharmaceuticals, Inc. (ACHN) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Piper Jaffray Upgrades Achillion Pharmaceuticals (ACHN) to Overweight
August 11, 2014 7:02 AM EDTPiper Jaffray upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Neutral to Overweight with a price target of $10.00 (from $5.00). Analyst Edward A. Tenthoff thinks potential suitors could emerge soon.
"Achillion ended 2Q:14 with cash of $131.5 million to advance its emerging HCV pipeline. Achillion... More
Wells Fargo Upgrades Achillion Pharmaceuticals (ACHN) to Outperform
August 11, 2014 6:19 AM EDTWells Fargo upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Market Perform to Outperform with a price target of $11-$13 (from $7-$8). Analyst Brian Abrahams is more confident as ACH-3422 progresses without incident, and he is optimistic on readouts for 3422 and 3102.
For an analyst ratings summary... More
